Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, placebo-controlled, double-blind, phase 3 study evaluating the pain palliation benefit of adding custirsen to a taxane for second-line chemotherapy in men with castrate resistance prostate cancer

Next Previous
Trial Profile

A randomized, placebo-controlled, double-blind, phase 3 study evaluating the pain palliation benefit of adding custirsen to a taxane for second-line chemotherapy in men with castrate resistance prostate cancer

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Jul 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Custirsen (Primary) ; Cabazitaxel; Docetaxel; Prednisone
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SATURN
  • Sponsors Achieve Life Sciences; OncoGenex Pharmaceuticals

Most Recent Events

  • 14 Jul 2019 Trial has been completed in UK, according to European Clinical Trials Database record.
  • 01 Aug 2017 According to Achieve Life Sciences media release, Achieve Life Sciences merged with OncoGenex Pharmaceuticals and the later changed its name to Achieve Life Sciences.
  • 11 Feb 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top